Cargando…
Routine HIV Screening in Portugal: Clinical Impact and Cost-Effectiveness
OBJECTIVE: To compare the clinical outcomes and cost-effectiveness of routine HIV screening in Portugal to the current practice of targeted and on-demand screening. DESIGN: We used Portuguese national clinical and economic data to conduct a model-based assessment. METHODS: We compared current HIV de...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3867470/ https://www.ncbi.nlm.nih.gov/pubmed/24367639 http://dx.doi.org/10.1371/journal.pone.0084173 |
_version_ | 1782296312092295168 |
---|---|
author | Yazdanpanah, Yazdan Perelman, Julian DiLorenzo, Madeline A. Alves, Joana Barros, Henrique Mateus, Céu Pereira, João Mansinho, Kamal Robine, Marion Park, Ji-Eun Ross, Eric L. Losina, Elena Walensky, Rochelle P. Noubary, Farzad Freedberg, Kenneth A. Paltiel, A. David |
author_facet | Yazdanpanah, Yazdan Perelman, Julian DiLorenzo, Madeline A. Alves, Joana Barros, Henrique Mateus, Céu Pereira, João Mansinho, Kamal Robine, Marion Park, Ji-Eun Ross, Eric L. Losina, Elena Walensky, Rochelle P. Noubary, Farzad Freedberg, Kenneth A. Paltiel, A. David |
author_sort | Yazdanpanah, Yazdan |
collection | PubMed |
description | OBJECTIVE: To compare the clinical outcomes and cost-effectiveness of routine HIV screening in Portugal to the current practice of targeted and on-demand screening. DESIGN: We used Portuguese national clinical and economic data to conduct a model-based assessment. METHODS: We compared current HIV detection practices to strategies of increasingly frequent routine HIV screening in Portuguese adults aged 18-69. We considered several subpopulations and geographic regions with varying levels of undetected HIV prevalence and incidence. Baseline inputs for the national case included undiagnosed HIV prevalence 0.16%, annual incidence 0.03%, mean population age 43 years, mean CD4 count at care initiation 292 cells/μL, 63% HIV test acceptance, 78% linkage to care, and HIV rapid test cost €6 under the proposed routine screening program. Outcomes included quality-adjusted survival, secondary HIV transmission, cost, and incremental cost-effectiveness. RESULTS: One-time national HIV screening increased HIV-infected survival from 164.09 quality-adjusted life months (QALMs) to 166.83 QALMs compared to current practice and had an incremental cost-effectiveness ratio (ICER) of €28,000 per quality-adjusted life year (QALY). Screening more frequently in higher-risk groups was cost-effective: for example screening annually in men who have sex with men or screening every three years in regions with higher incidence and prevalence produced ICERs of €21,000/QALY and €34,000/QALY, respectively. CONCLUSIONS: One-time HIV screening in the Portuguese national population will increase survival and is cost-effective by international standards. More frequent screening in higher-risk regions and subpopulations is also justified. Given Portugal’s challenging economic priorities, we recommend prioritizing screening in higher-risk populations and geographic settings. |
format | Online Article Text |
id | pubmed-3867470 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-38674702013-12-23 Routine HIV Screening in Portugal: Clinical Impact and Cost-Effectiveness Yazdanpanah, Yazdan Perelman, Julian DiLorenzo, Madeline A. Alves, Joana Barros, Henrique Mateus, Céu Pereira, João Mansinho, Kamal Robine, Marion Park, Ji-Eun Ross, Eric L. Losina, Elena Walensky, Rochelle P. Noubary, Farzad Freedberg, Kenneth A. Paltiel, A. David PLoS One Research Article OBJECTIVE: To compare the clinical outcomes and cost-effectiveness of routine HIV screening in Portugal to the current practice of targeted and on-demand screening. DESIGN: We used Portuguese national clinical and economic data to conduct a model-based assessment. METHODS: We compared current HIV detection practices to strategies of increasingly frequent routine HIV screening in Portuguese adults aged 18-69. We considered several subpopulations and geographic regions with varying levels of undetected HIV prevalence and incidence. Baseline inputs for the national case included undiagnosed HIV prevalence 0.16%, annual incidence 0.03%, mean population age 43 years, mean CD4 count at care initiation 292 cells/μL, 63% HIV test acceptance, 78% linkage to care, and HIV rapid test cost €6 under the proposed routine screening program. Outcomes included quality-adjusted survival, secondary HIV transmission, cost, and incremental cost-effectiveness. RESULTS: One-time national HIV screening increased HIV-infected survival from 164.09 quality-adjusted life months (QALMs) to 166.83 QALMs compared to current practice and had an incremental cost-effectiveness ratio (ICER) of €28,000 per quality-adjusted life year (QALY). Screening more frequently in higher-risk groups was cost-effective: for example screening annually in men who have sex with men or screening every three years in regions with higher incidence and prevalence produced ICERs of €21,000/QALY and €34,000/QALY, respectively. CONCLUSIONS: One-time HIV screening in the Portuguese national population will increase survival and is cost-effective by international standards. More frequent screening in higher-risk regions and subpopulations is also justified. Given Portugal’s challenging economic priorities, we recommend prioritizing screening in higher-risk populations and geographic settings. Public Library of Science 2013-12-18 /pmc/articles/PMC3867470/ /pubmed/24367639 http://dx.doi.org/10.1371/journal.pone.0084173 Text en © 2013 Yazdanpanah et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Yazdanpanah, Yazdan Perelman, Julian DiLorenzo, Madeline A. Alves, Joana Barros, Henrique Mateus, Céu Pereira, João Mansinho, Kamal Robine, Marion Park, Ji-Eun Ross, Eric L. Losina, Elena Walensky, Rochelle P. Noubary, Farzad Freedberg, Kenneth A. Paltiel, A. David Routine HIV Screening in Portugal: Clinical Impact and Cost-Effectiveness |
title | Routine HIV Screening in Portugal: Clinical Impact and Cost-Effectiveness |
title_full | Routine HIV Screening in Portugal: Clinical Impact and Cost-Effectiveness |
title_fullStr | Routine HIV Screening in Portugal: Clinical Impact and Cost-Effectiveness |
title_full_unstemmed | Routine HIV Screening in Portugal: Clinical Impact and Cost-Effectiveness |
title_short | Routine HIV Screening in Portugal: Clinical Impact and Cost-Effectiveness |
title_sort | routine hiv screening in portugal: clinical impact and cost-effectiveness |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3867470/ https://www.ncbi.nlm.nih.gov/pubmed/24367639 http://dx.doi.org/10.1371/journal.pone.0084173 |
work_keys_str_mv | AT yazdanpanahyazdan routinehivscreeninginportugalclinicalimpactandcosteffectiveness AT perelmanjulian routinehivscreeninginportugalclinicalimpactandcosteffectiveness AT dilorenzomadelinea routinehivscreeninginportugalclinicalimpactandcosteffectiveness AT alvesjoana routinehivscreeninginportugalclinicalimpactandcosteffectiveness AT barroshenrique routinehivscreeninginportugalclinicalimpactandcosteffectiveness AT mateusceu routinehivscreeninginportugalclinicalimpactandcosteffectiveness AT pereirajoao routinehivscreeninginportugalclinicalimpactandcosteffectiveness AT mansinhokamal routinehivscreeninginportugalclinicalimpactandcosteffectiveness AT robinemarion routinehivscreeninginportugalclinicalimpactandcosteffectiveness AT parkjieun routinehivscreeninginportugalclinicalimpactandcosteffectiveness AT rossericl routinehivscreeninginportugalclinicalimpactandcosteffectiveness AT losinaelena routinehivscreeninginportugalclinicalimpactandcosteffectiveness AT walenskyrochellep routinehivscreeninginportugalclinicalimpactandcosteffectiveness AT noubaryfarzad routinehivscreeninginportugalclinicalimpactandcosteffectiveness AT freedbergkennetha routinehivscreeninginportugalclinicalimpactandcosteffectiveness AT paltieladavid routinehivscreeninginportugalclinicalimpactandcosteffectiveness |